Huons Global Co. Ltd Cash Flow Conversion Efficiency
Huons Global Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, Huons Global Co. Ltd (084110) has a cash flow conversion efficiency ratio of 0.020x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩22.29 Billion ≈ $15.11 Million USD) by net assets (₩1.09 Trillion ≈ $737.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Huons Global Co. Ltd (2010–2025)
Cash flow conversion efficiency of Huons Global Co. Ltd from 2010 to 2025. This chart illustrates how Huons Global Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Huons Global Co. Ltd share price for real-time trading data and today's change.
Huons Global Co. Ltd Cash Flow Conversion Ratio Explained
Huons Global Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Huons Global Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Huons Global Co. Ltd ranked by their cash flow conversion efficiency. Also see Huons Global Co. Ltd (084110) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BJC Heavy Industries Public Company Limited
BK:BJCHI
|
0.054x |
|
Mnc Land Tbk
JK:KPIG
|
0.018x |
|
Motonic
KO:009680
|
0.027x |
|
Sun Tekstil Sanayi ve Ticaret A.S.
IS:SUNTK
|
0.091x |
|
Dong Hai JSC of Bentre
VN:DHC
|
0.005x |
|
Bank Net Indonesia Syariah Tbk PT
JK:BANK
|
0.102x |
|
Namyong Terminal PCL
BK:NYT
|
0.085x |
|
HUYA Inc
NYSE:HUYA
|
N/A |
Annual Cash Flow Conversion Efficiency for Huons Global Co. Ltd (2010–2025)
The table below shows the annual cash flow conversion efficiency of Huons Global Co. Ltd from 2010 to 2025. Review 084110 free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩1.09 Trillion ≈ $739.51 Million |
₩93.61 Billion ≈ $63.44 Million |
0.086x | -55.64% |
| 2024-12-31 | ₩520.11 Billion ≈ $352.47 Million |
₩100.57 Billion ≈ $68.16 Million |
0.193x | +76.15% |
| 2023-12-31 | ₩910.68 Billion ≈ $617.15 Million |
₩99.97 Billion ≈ $67.75 Million |
0.110x | -19.15% |
| 2022-12-31 | ₩464.32 Billion ≈ $314.66 Million |
₩63.04 Billion ≈ $42.72 Million |
0.136x | +46.56% |
| 2021-12-31 | ₩537.84 Billion ≈ $364.49 Million |
₩49.82 Billion ≈ $33.76 Million |
0.093x | -57.79% |
| 2020-12-31 | ₩412.83 Billion ≈ $279.77 Million |
₩90.59 Billion ≈ $61.39 Million |
0.219x | +26.73% |
| 2019-12-31 | ₩378.53 Billion ≈ $256.52 Million |
₩65.55 Billion ≈ $44.42 Million |
0.173x | +17.42% |
| 2018-12-31 | ₩362.21 Billion ≈ $245.47 Million |
₩53.42 Billion ≈ $36.20 Million |
0.147x | +5.87% |
| 2017-12-31 | ₩341.14 Billion ≈ $231.19 Million |
₩47.52 Billion ≈ $32.20 Million |
0.139x | +129.81% |
| 2016-12-31 | ₩319.80 Billion ≈ $216.72 Million |
₩19.38 Billion ≈ $13.14 Million |
0.061x | -79.89% |
| 2015-12-31 | ₩168.94 Billion ≈ $114.49 Million |
₩50.91 Billion ≈ $34.50 Million |
0.301x | +97.16% |
| 2014-12-31 | ₩188.38 Billion ≈ $127.66 Million |
₩28.79 Billion ≈ $19.51 Million |
0.153x | -22.72% |
| 2013-12-31 | ₩125.24 Billion ≈ $84.87 Million |
₩24.77 Billion ≈ $16.79 Million |
0.198x | +2.71% |
| 2012-12-31 | ₩92.92 Billion ≈ $62.97 Million |
₩17.89 Billion ≈ $12.13 Million |
0.193x | +125.39% |
| 2010-12-31 | ₩78.18 Billion ≈ $52.98 Million |
₩6.68 Billion ≈ $4.53 Million |
0.085x | -- |
About Huons Global Co. Ltd
Huons Global Co., Ltd. provides medical solutions for human health in South Korea and internationally. The company offers oral solid form products in the areas of circulatory system, metabolic, anti-pyretic analgesic anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, antibiotic, well-being, urogenital system, other chemotherapeutic, and others; and inj… Read more